ScrollScroll
Scroll

About Us

FuturedMe was launched based on “CANDDY™” an original technology of drug design developed by Tokyo University of Science. CANDDY™ compounds induce degradation, NOT inhibition of the targets related diseases. FuturedMe brings CHANGE to you with “Future medicine”.

Scroll

Mission

Our mission is to bring each medicine to each patient who do not have any medicine (No Patients without Medicine™). Nowadays you know genes related your disease with gene panels as a diagnosis, however, 20-30% of you do NOT have any specific medicines. Our goal is to bring each medicine to every single patient. We change undruggable target to druggable one with CANDDY™ technology.

Scroll

Our ScienceOur Science

FuturedMe is a pioneer in the science of using CANDDY™ Platform—new protein degradation platform—to make new small molecules as drug candidates. CANDDY™ technology has invented by Tokyo University of Science, professor Etsuko Miyamoto-Sato. CANDDY™ is a ubiquitin-INDEPENDENT and direct proteasomal degradation technology, which can break down proteins of interest using the cell’s natural protein degradation machinery rather than merely inhibiting the function of the proteins, as traditional drugs do. The benefit is versatility and flexibility in more simply designing and profiling. CANDDY™ is a technology that would release any patients from their agonies and delivering healthy life.

Scroll

Member

Katsuya Hashizume Katsuya Hashizume Katsuya HashizumeChief Executive Officer
CLOSE
Katsuya Hashizume
Katsuya HashizumeChief Executive Officer
Katsuya Hashizume

Mr. Hashizume represents FuturedMe as CEO. He launched FuturedMe with Prof. Miyamoto-Sato after three years project supported by START program of Japan Science and Technology Agency. He leads Academic Corporate Liaison Investment Group at JAFCO and leads, as an external board director, early-stage companies launched from universities. He joined JAFCO in 2010 and leads Academic Corporate Liaison Investment Group at JAFCO. He received a Master of Media and Governance from Keio University.

Etsuko Miyamoto-Sato Etsuko Miyamoto-Sato Etsuko Miyamoto-Sato, Ph. D.Founder & Director
CLOSE
Etsuko Miyamoto-Sato Etsuko Miyamoto-Sato

Dr. Miyamoto-Sato is a founder and director at FuturedMe and established CANDDY™ technology at Tokyo University of Science (TUS). She leads CANDDY™ Project as Professor of Molecular Medical Science Lab. at Research Institute for Science & Technology, TUS. She joined the Genome Network Project (MEXT, Japan) as Associate Prof. of Keio University, followed by a department head of Interactome Medical Science at the Institute of Medical Science, The Univ. of Tokyo. She had stayed in Carnegie Mellon University from 1997 to 1999 during researching in Mitsubishi Life science Institute from 1995 to 2000. After graduating from TUS, she started her carrier at IBM Yamato Lab in Japan, followed by working for Toshiba Information Research Center. She received a Ph.D. in Science and Technology from University National Yokohama.

Masamichi Ishizaka Masamichi Ishizaka Masamichi Ishizaka, Ph. D.Head of chemical Biology
R&D Department
CLOSE
Masamichi Ishizaka
Masamichi Ishizaka, Ph. D.Head of chemical Biology
R&D Department
Masamichi Ishizaka

Dr. Ishizaka joined as Head of Chemical Biology to develop CANDDY™ platform. Prior to joining FuturedMe, he worked as a researcher in a biotech company and as a searcher/analyst at a patent search corporation. He developed High-throughput screening platforms in the Genome Network Project (MEXT, Japan). He had researched detecting protein-protein interaction with mRNA display method (IVV technology). He led cutting-edge projects as a assistant professor at Keio University. He received a Ph.D. in Science from Kyushu University.

Makoto Jitsuoka Makoto Jitsuoka Makoto JitsuokaHead of chemistry
R&D Department
CLOSE
Makoto Jitsuoka
Makoto JitsuokaHead of chemistry
R&D Department
Makoto Jitsuoka

Mr. Jitsuoka joined FuturedMe in 2019 as Head of Chemistry, bringing expertise in pharmaceutical industry and scientific leadership to develop new medical drugs with CANDDY™ technology. He has over 20 years experiences at three different domestic and international pharmaceutical companies as a medicinal chemist. He has experience of developing new medical drugs with not only chemical compounds but also proteins and antibodies and GMP. His experience develops our platform and pipeline with CANDDY™ technology. He received a Master of applied chemistry from Keio University.

Tomohiro Yamaguchi Tomohiro Yamaguchi Tomohiro Yamaguchi, Ph. D.Senior Researcher of Chemical Biology R&D Department
CLOSE
Tomohiro Yamaguchi
Tomohiro Yamaguchi,
Ph. D.Senior Researcher of Chemical Biology
R&D Department
Tomohiro Yamaguchi

Dr. Yamaguchi joined as a senior researcher to develop CANDDY™ platform based on structural biology. Prior to FuturedMe, he has studied protein structural biology for 16 years at Kyushu University, Japan Biological Informatics Consortium, RIKEN, and graduate school of pharmaceutical science of Kyoto University. He has expertise in analyzing recombinant proteins such as membrane proteins. He revealed the X-ray structure of P-glycoprotein complexed with a unique allosteric inhibitor. He received Ph.D. of Science (Biophysics) from Kyoto University.

Keiko Kaneko Keiko Kaneko Keiko Kaneko, Ph. D.Senior Researcher of Biology
R&D Department
CLOSE
Keiko Kaneko
Keiko
Kaneko, Ph. D.Senior Researcher of Biology
R&D Department
Keiko Kaneko

Dr. Kaneko joined as a senior researcher to develop CANDDY™ pipeline based on biology. She started her career as a researcher in National Institute for Physiological Sciences after obtaining a Ph.D. of Medicine from Yokohama City University in 2007. She had researched bone metabolism with genetic models in National Center Geriatrics and Gerontology 2008 to 2014. Prior to join FuturedMe, she had worked as a postdoctoral associate to research bone development and regeneration with mesenchymal lineage cells in University of Rochester, Washington University in St. Louis and University of Michigan, USA.

Megumi Saito Megumi Saito Megumi Saito, Ph. D.Visiting Researcher
R&D Department
CLOSE
Megumi Saito
Megumi
Saito, Ph. D.Visiting Researcher
R&D Department
Megumi Saito

Dr. Saito joined FuturedMe as a visiting researcher to develop CANDDY™ technology with animal models. She previously worked in cutting-edge research using mouse models at Chiba Cancer Research Institute. She found new functions of p53 related genes in sporadic cancer as her thesis. She received a Ph.D. in Medical Science from Department of Molecular Biology and Oncology, Chiba University in 2019.

Megumi Tsukamoto Megumi Tsukamoto Megumi Tsukamoto, Ph. D.Visiting Researcher
R&D Department
CLOSE
Megumi Tsukamoto
Megumi Tsukamoto,
Ph. D.Visiting Researcher
R&D Department
Megumi Tsukamoto

Dr. Tsukamoto joined as a visiting researcher at FuturedMe to develop new medical drugs with CANDDY™ technology. She previously researched the risk of developing disease based on specific membrane transporters as a research trainee in the Division of Cancer Epidemiology and Prevention at Aichi Cancer Center Research Institute. She received as Ph.D. in applied biology from Chubu University in 2019.

Minazu Hara Minazu Hara Minazu HaraAdministration
CLOSE
Minazu Hara
Minazu HaraAdministration
Minazu Hara

Ms.Hara is an administrator in the management department. She is a specialist of general affairs, accounting, and labor in general. She worked as an administration of CEO at secretary at accounting offices and several companies.

Scroll

Corporate OverviewCorporate Overview

Registered NameFuturedMe Inc.
Date of EstablishmentJune 26th, 2018
Number of Employees9 (including 6 Ph.D. as of Apr 2019)
LocationHead Office / 2-3-11, Nihonbashi Honcho, Chuo-ku, Tokyo Japan
Research Laboratories / 2641, Yamazaki, Noda, Chiba Japan
Directors
CEO
Katsuya Hashizume
Founder
Etsuko Miyamoto-Sato, Ph.D.
Professor of Tokyo University of Science
Our BankMizuho Bank, Ltd.Mizuho Bank, Ltd.
InvestorJAFCO Co., Ltd.JAFCO Co., Ltd.